ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
Merck (MRK) and Moderna (MRNA) presented Phase 3 trial data for their cancer vaccine, showing a 42% reduction in recurrence or death risk. Analysts now view the results positively, despite initial market selloff. The treatment combo includes Keytruda and intismeran autogene. Moderna's stock fell 7% premarket but is up 700% year-to-date. Additional data is expected in other cancer types.
How this was made
The 30-second read
Why it matters
The leak triggered a selloff, but the subsequent presentation and analyst commentary reframed the interim hazard ratio as meaningful, while emphasizing that overall survival data is not yet available and that competitive positioning versus BMS remains uncertain.
Market read
Traders get a catalyst-driven repricing signal for both MRNA and MRK tied to interim Phase 3 oncology efficacy, with OS uncertainty and competitive benchmarks still driving risk.
What to watch
Clinical-practice adoption may hinge on tolerability versus dual checkpoint blockade, and the article flags serious adverse event rates as a key differentiator that could matter more than the interim efficacy headline.
Background
Phase 3 INTerpath-001 melanoma results for Moderna’s intismeran plus Merck’s Keytruda were published early after an online leak ahead of an ESMO presentation.
Ticker impact
Merck’s Phase 3 INTerpath-001 melanoma data leaked early, and analysts now view the intismeran plus Keytruda hazard ratio as acceptable despite initial disappointment.
Likely reduced downside pressure versus the initial selloff as analysts reframe the interim benefit and await longer follow-up.
The article attributes the selloff to disappointment around the hazard ratio threshold, then cites analyst notes softening after additional presentation details and longer-term hazard ratio commentary.
Moderna’s intismeran/Keytruda Phase 3 INTerpath-001 melanoma results leaked ahead of ESMO, triggering a premarket drop before analysts warmed to the interim benefit.
Likely choppy trading with bias toward stabilization as the market digests the interim efficacy and longer follow-up hazard ratio discussion.
The piece reports a 7% premarket decline tied to the leak and hazard ratio framing, then adds analyst confidence on OS not yet reached and a lower hazard ratio at later timepoints.
Market effects
Reinforces investor focus on personalized mRNA oncology platforms and how interim hazard ratios are being interpreted versus checkpoint-monotherapy benchmarks.
Primarily US biotech sentiment spillover tied to an ESMO catalyst, with European conference coverage influencing global risk appetite for oncology trial readouts.
Highlights how trial-data leakage and conference timing can drive short-term repricing in global biotech markets.
Counterpoint
Even with an interim hazard ratio near the desired range, the lack of overall survival data and head-to-head uncertainty versus Bristol Myers Squibb’s NADINA standard could cap enthusiasm.
Key entities
- companyMerck
Partner in the intismeran plus Keytruda Phase 3 INTerpath-001 melanoma program; shares sold off on the leak, then analysts warmed to the interim hazard ratio.
- companyModerna
Develops intismeran; shares declined premarket after the leak, then received more constructive analyst interpretation after ESMO details.
- companyBristol Myers Squibb
Referenced for the NADINA trial benchmark (Opdivo and Yervoy) that sets a competitive standard and influences how intismeran may be positioned.
- eventEuropean Society of Medical Oncology (ESMO)
Conference where the trial presentation occurred, shaping the timing and market reaction to the leaked data.
